AMLcombine® is intensely focused on our shared vision of true collaboration among academic clinicians, translational and basic scientists and BioPharmas to break through the silos of R&D in AML and rapidly advance the full exploitation of emerging targets, novel therapeutics and radical/rational regimens to defeat this tragic disease.
Our Global Collaborative Research Group and Global Scientific Meetings will bring together a distinguished group of worldwide experts, by invitation only.
We’ve held our initial Organizational Start-up Meeting in February 2017. We then convened our first AMLcombine Global Scientific Meeting in September. We have accumulated a list of all current AML vulnerabilities (targets), major AML discovery research efforts and novel targeted products in development for AML.
Listed below are a few of the leading web-based AML clinical and research resources for Physicians and Medical Professionals . Some websites may require Log-in account information, subscription, or registration upon visiting:
National Comprehensive Cancer Network (NCCN) in the U.S.,
AML Clinical Practice Guidelines for Diagnosis and Treatment of AML (2016)
(Page 2 provides a list of the 29 AML clinical research experts who composed the most recent AML Guidelines panel)
Click on the NCCN Network Cancer Centers to obtain more information about the cancer center and to find links to the NCCN Member Institution’s web site
The European LeukemiaNet (ELN) has established an “AML Working Party” (WP5)
of clinical and laboratory research experts, as well as the publication of their
2009 Recommendations, Manuscript in Blood, and a list of all AML WP5 Expert Participants (2014):
The European Haematology Association has established the
“AML Scientific Working Group” of expert clinicians, who publish summaries
of their collaborative research meetings:
The government of the European Union has originated and funded a groundbreaking research initiative, beginning with AML, to collect and assess patient-level diagnostic, clinical, treatment and outcomes data. The HARMONY program will employ artificial intelligence algorithms to enable prospective questions to be addressed by a large foundation of data on AML and traditional and emerging novel therapies.
Additional information on Individual Patient INDs and Expanded Access Clinical Trials may be found on our PATIENT RESOURCES page.